Dr. Zamarin on the Future Treatment Landscape of Gynecologic Malignancies

Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future treatment landscape for patients with gynecologic malignancies.

According to Zamarin, the first drugs that will be approved will be more of the standard off-the-shelf treatments, such as immune checkpoint blockade or vaccines.

The adoptive T-cell therapies will be are more involved and more expensive, states Zamarin. The recent product that was approved from Novartis for the treatment of patients with leukemia is very expensive per treatment, which may become a limitation of choosing some of these therapies. If the therapies resolve in long-term disease stabilization or even cures of these patients, perhaps these types of treatments will justify the costs, explains Zamarin.